Previous studies have demonstrated little efficacy of interferons (IFNs) in animal models of Ebola virus disease. However, these studies were limited to a small number of type I IFNs and, during the most recent outbreak of Ebola virus, questions regarding the suitability of the animal models to evaluate IFNs were raised. To address the potential that anti-Ebola virus activity was overlooked, type I and type II IFNs (α-2a, α-2b, -β, -γ, and -universal) were tested in a variety of cell types (Vero E6, Huh 7 cells, and human macrophages). IFNs are weak inhibitors of Ebola virus Makona in these cell lines.
In December 2013, an Ebola virus disease (EVD) epidemic of unseen proportions erupted in Western Africa. The outbreak continued to fester despite local, national and international engagement for over 2 years, making the Western Africa Ebola crisis the largest EVD outbreak on record.
The high mortality of EVD in combination with a lack of available treatments and modern hospital settings continues to make clinical management of EVD patients in Western Africa challenging and dangerous. The magnitude of the recent epidemic has brought about renewed interest in repurposing easily accessible drugs for EVD treatment. Evaluation of approved antivirals continues to be a priority. During the course of this outbreak, a number of candidate therapeutics were evaluated both in controlled clinical trials and through off-label use by prescribing physicians. Interferons (IFNs) are one class of drugs that eventually entered into a clinical trial at the end of the epidemic [1] . Although no data have been published yet, the small number of EVD patients (9) and lack of a placebo control arm may make it difficult to draw meaningful conclusions on the value of IFN treatment [1] .
In filovirus-infected nonhuman primates (NHPs), INF treatment reduced viremias, delayed the time to death, and, for Marburg virus, reduced mortality, indicating that IFNs may have value as an adjunctive postexposure treatment in combination with other treatments [2] [3] [4] .
Anti-Ebola virus (EBOV) activity of type I IFNs (IFN-α, IFN-β) was tested in vivo and in vitro, and type II IFN (IFN-γ) activity has only been tested in vitro [5, 6] . So far, no studies have tested INFs for efficacy against Makona isolate of EBOV (EBOV/Mak). Synergistic effects using combinations of type I and type II IFNs have been described for viruses such as hepatitis C virus [7] , but not evaluated for EBOV. Finally, concerns were raised that divergence in the IFN pathways between humans and NHPs or the use of a human IFN product in NHPs may not fully predict the potential anti-EBOV activities of IFNs in humans. To address these points, we evaluated the efficacy of recombinant IFNs (type I and II) against EBOV/Mak in vitro in established and primary cells, both as single compounds and combinations of compounds.
METHODS

Cell Lines and Virus
Vero E6 (ATCC number 1568, Manassas, Virginia) and Huh 7 (human hepatocellular carcinoma) cells were maintained in Dulbecco's modified Eagle's medium (DMEM) plus 10% fetal bovine serum (FBS). Human monocyte-derived macrophages (MDMs) were cultured from fresh whole blood obtained from the National Cancer Institute Research Donor Program, National Institutes of Health blood bank (Bethesda, Maryland) as previously described [2, 8] . Ebola virus/H.sapiens-tc/GIN/14/WPG-C05 (EBOV/Mak, GenBank accession number KP096420) was prepared as previously described prior to use [8] .
Cell-Based Enzyme-Linked Immunosorbent Assay Screen for Ebola Virus
Antiviral Agents
For all drug screens, efficacy and cytotoxicity studies were performed in parallel. Vero E6 and Huh 7 cells were seeded at 30 000 cells, and MDMs were seeded at 100 000 cells in 100 µL of DMEM plus 10% FBS per well in black, clear bottom 96-well plates. Test compounds included IFN-β (Pestka Biomedical Laboratories [PBL] number 11415-1; Piscataway, New Jersey), IFN-α-2a (PBL number 11101-5), IFN-α-2b (PBL number 11105-1), IFN-γ (PBL number 11500-2), and a recombinant product based on the consensus sequence of the IFN-αA and -αD subtypes designated as "universal type 1 IFN" (PBL number 11200-1). Three-fold dilutions (1.6-5000 U/mL) of IFNs were added to the cells 1 hour or 24 hours prior to virus inoculation with EBOV/Mak at an multiplicity of infection (MOI) of 0.1 or 2.5 (Vero E6, Huh 7 cells) or 0.1 or 2 (MDM) in 50 µL of DMEM plus 10% FBS. After 48 hours, plates were fixed with 10% neutral-buffered formalin and removed from biocontainment following standard safety protocols. EBOV/Mak was detected with a mouse anti-EBOV VP40 antibody (number B-MD04-BD07-AE11,) followed by staining with Alexa Fluor 594-labeled immunoglobulin G (IgG) antibody (number A11005, Life Technologies, Grand Island, New York) or peroxidase-labeled IgG-antibody (KPL number 074-1802). Fluorescence (excitation, 590 nm; emission, 617 nm) or luminescence was quantified on a plate reader (Infinite M1000 Pro, Tecan US, Morrisville, North Carolina).
Cytotoxicity was measured 48 hours after drug addition on non-virus-infected plates using Cell Titer Glo luminescent cell viability assay kit (Promega, Madison, Wisconsin) and luminescence was read on the Infinite M1000 Pro plate reader.
Testing Drug Combinations for Synergy
IFN-β and IFN-γ combinations were prepared in a 5 × 5 matrix with 1:10 dilutions and at an initial concentration of 5000 U/mL and transferred to triplicate cell plates for the enzyme-linked immunosorbent assay (ELISA) and the cytotoxicity assay, respectively.
Data Analysis
Following background subtraction, inhibition was measured as percentage relative to untreated infected cells. Nonlinear regression analysis was performed, and 50% inhibitory concentration (IC 50s ) were calculated from fitted curves (log [agonist] vs response [variable slope] with constraint to remain above 0; GraphPad Software, La Jolla, California). The EBOV-ELISA drug screen was carried out with 3 replicates for each drug concentration, and the assay was repeated at least twice for confirmation. Error bars represent the standard deviation of the 3 replicate dose-response curves. Drug interactions were characterized using the 3-dimensional analysis by MacSynergy II [9] . Synergy volumes were determined at 99.9% confidence interval and are given in units of uM 2 %, which is analogous to the units for the area under a dose-response curve in the 2-dimensional situation (uM%). (Figure 1 and Table 1 ). Other type I IFNs, IFN-α-2a, IFN-α-2b, and IFN-universal, were active with the maximum effect reaching 100% at 5000 U/mL. (Supplementary Figure 1 and Table 1 ). Potency with these IFNs was lower (IC 50 ranging from 96 to 326 U/mL) than that obtained with IFN-β. The antiviral activity of IFN-γ was not as strong as for the type I IFNs with maximum effect only reaching 38%-72% at highest dose tested (Figure 1 and Table 1 ). When reducing pretreatment to 1 h before virus challenge with an MOI of 0.1, IFN-β demonstrated anti-EBOV activity with IC 50s of 10, 31.3, and 235 U/mL in MDMs, Huh 7, and Vero E6 cells, respectively (Table 1) . However, IFN-γ had even weaker activity with the maximum effect not exceeding 50% (Table 1) . We next investigated the antiviral effect of IFNs following infection with a higher MOI. Infecting Vero E6 and Huh 7 cells at an MOI of 2.5 led to 60% and 80% infected cells, respectively, at the 48-hour endpoint of the assay (data not shown). MDMs inoculated at an MOI of 2 resulted in 95% of cells being infected (data not shown). At a higher MOI with 1 hour pretreatment, the IFNs showed either no or weak activity against the Makona variant of EBOV in all cell types tested (Table 1) . Toremifene citrate, a well-known inhibitor of EBOV [10] , was used as a positive control in all experiments and showed inhibition with IC 50 s in the range of 1.2-6.8 µM (data not shown).
To investigate potential drug synergy effects between type I and II IFNs on the inhibition of EBOV replication, serial dilutions of IFN-β and IFN-γ were combined in a 5 × 5-matrix and tested against EBOV/Mak in Vero E6, Huh 7 cells, and MDMs. Cells were pretreated with IFNs, and inhibition of replication was determined using a cell-based ELISA at 48 hours after inoculation. Results of drug interactions are presented as 3-dimensional surface plots with MacSynergy II software (Supplementary Figure 2) . The percentage change in surface volume above or below the null reference plane is indicative of synergy or antagonism, respectively. Synergy volumes were used to calculate the net effect of drug combinations (Supplementary Table 1 ). According to the MacSynergy classification system, the overall effect of combinations was additive. Insignificant levels of synergy were detected at the highest dose of IFN-γ (5000 U/mL) tested in Vero E6 cells (MOI of 2.5, 24 hours pretreatment) and Huh 7 cells (MOI of 1, 1 hour pretreatment).
DISCUSSION
These results are consistent with previous reports evaluating IFNs for antiviral activity against EBOV [5, 6] . As expected, the pretreatment of the cells and use of the lowest MOIs provided the most favorable experimental conditions for viral inhibition by IFNs. In vitro inhibition of EBOV/Mak with IFN-β was detected with IC 50s in the range of 10-20 U/mL with 24-hour pretreatment at MOI 0.1. These concentrations correspond to 56-112 pg/mL (specific activity 1.77 × 10 8 U/mg; PBL number 11415-1) and are 3-to 6-fold above the peak plasma concentration (20 pg/mL) achieved clinically with the pegylated form of IFN-β [11] . Of note, these experiments found that the type II IFN (IFN-γ) inhibited only 38%-72% of EBOV infection at 5000 U/mL, which corresponds to 300 ng/mL (specific activity 1.42 × 10 7 U/mg) [12] . This concentration is several logs higher than peak serum concentrations of 0.6 or 1.5 ng/mL following subcutaneous or intramuscular injection of IFN-γ-1b, respectively, in the clinic [13] . IFNs were also tested using higher virus input (MOI = 1-2.5) resulting in a significant decrease in measured activity. Recently, human IFN-γ was shown to have an anti-EBOV effect in human primary macrophages [6] . However, this study measured activity against recombinant vesicular stomatitis virus expressing the EBOV-glycoprotein and not infectious EBOV/Mak as presented here, making it difficult to directly compare results [6] .
While in vitro evaluation demonstrated a weak antiviral effect of IFNs, in vivo models will also evaluate the indirect effect of IFNs on the immune system (eg, natural killer cell activation) that could impact survival. IFN treatment in animal models of EBOV infection has given mixed results. Murine IFN-γ was shown to have antiviral activity in murine primary macrophages and led to protection of mice from a lethal challenge of mouse-adapted EBOV [6] . In contrast, IFN-β treatment had a much weaker therapeutic effect and ultimately did not protect NHPs from EBOV infection [4] .
Combination therapy with type I and II IFNs [10] theoretically could lower the individual IFN dosage requirements. This study did not detect a synergistic effect of IFN-β (type I) and IFN-γ (type II) against EBOV/Mak at a clinically achievable dosage range. However, this study was limited in nature and did not explore temporal dosing strategies.
The consistent observation of peak anti-EBOV activity when cells are pretreated for 24 hours with IFN supports the theory of a competition between the virus to subvert the host's ability to respond to IFN (endogenous or exogenous) and the body's attempt to establish an antiviral state. Surprisingly, increased levels of IFN-α and -β have been reported in EBOV-infected NHPs at the end stages of disease, after widespread infection of cells and tissues [14] . These in vitro and in vivo data suggest that timing of the INF response may be critical for virus control.
Apart from the 24-hour pretreatment, the activity of IFNs were dependent on lower MOIs, highlighting the importance of knowing the conditions in which a drug was tested. This becomes especially critical when sharing data within the international scientific community. We recommend as "best practices" documentation of in vitro activity data using multiple MOIs and cell lines including one primary cell type (eg, MDMs).
In conclusion, the data presented here suggest that IFN will unlikely have a beneficial effect in EVD patients and will likely only have value if treatment is initiated very early in disease progression at a time when viremia is still low. In addition, these drugs are associated with a number of side effects including fever, myalgia, nausea, and vomiting (at higher doses) that could exacerbate the disease symptoms in EVD patients. While IFNs have the advantage of being easily accessible and available, select candidate countermeasures with proven efficacy in NHPs (eg, GS-5734) are now available even after the onset of the clinical disease [15] . The demonstrated benefit of these countermeasures in NHPs suggests that they should be the lead candidates for advancement or use in clinical trials.
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